Introduction: Why Credentials Alone Do Not Predict Outcomes

Every existing article on choosing a stem cell clinic — including ours — tells you to verify credentials, check the facility license, look at testimonials, ask about cost transparency, and watch for unrealistic promises. All necessary. None of it sufficient.

The credentials framework is binary. Either the doctor is RETHUS-verified or not. Either the clinic has REPS Habilitación or not. Either the product is GMP-sourced or not. Once you have confirmed the binary checks (start with our companion piece "Verifying Your Medellín Peptide Clinic on Day 1" if you have not), the binary framework is exhausted and the question becomes: among the credentialed clinics, how do I tell the genuinely competent stem cell practice from the credentialed-but-low-volume practice that happens to also offer stem cell therapy?

A doctor can pass every binary check on Day 1 and still be the wrong physician for a stem cell procedure because they have personally performed three of them in the past year. A clinic can have an immaculate facility license and still have no structured adverse event tracking system or 12-month follow-up infrastructure. Credentials are necessary. They are not sufficient.

This 2026 verification framework is the second-layer article — the volume-and-experience layer that goes beyond credentials. It is for U.S. patients evaluating stem cell therapy in Medellín who have already done the basic credential checks and want to know how to ask the questions that actually predict procedural outcomes.

The Volume-Outcome Relationship: Why It Applies to Stem Cell Therapy

In procedural medicine generally, the volume-outcome relationship is one of the most consistent findings in the health-services literature. For dozens of high-acuity procedures — from coronary artery bypass grafting to pancreaticoduodenectomy to total joint arthroplasty to carotid endarterectomy to bariatric surgery — higher-volume operators and higher-volume facilities have measurably better outcomes than lower-volume operators and facilities. The difference is not subtle. For some procedures the mortality difference between the highest-volume and lowest-volume quintiles approaches a factor of two or three.

The mechanism is intuitive. Procedural medicine has a learning curve. The thousandth case is performed differently from the tenth case. Tissue handling is more refined, anticipation of variation is sharper, complication recognition and management is faster, the entire team's choreography is tighter.

Stem cell therapy is procedural medicine. It involves harvest (for autologous adipose-derived protocols, a mini-liposuction), processing (cell isolation, viability testing, dose preparation), administration (intra-articular injection, IV systemic, intrathecal, scalp microinjection, etc.), and post-procedure care. Each step has its own learning curve. A physician performing their thirtieth adipose mini-liposuction this year is operating differently from a physician performing their third.

The volume-outcome relationship for stem cell therapy specifically is less rigorously studied than for established surgical specialties — the field is younger and the registries are thinner — but the underlying logic is the same. Volume matters. The patient has the right to ask.

The Four-Domain Verification Framework

Beyond the binary credential checks, four domains of verification predict procedural outcomes:

Physician procedural volume by procedure type
Cell processing facility specifications and chain of custody
Adverse event tracking systems and rate
Long-term follow-up infrastructure (6-month and 12-month outcome data)

Each domain has specific questions to ask, realistic answers that signal a serious practice, and red-flag answers that signal a clinic that has not built the underlying infrastructure.

Domain 1: Physician Procedural Volume

Stem cell therapy is not one procedure. It is a family of procedures. A physician's volume matters per procedure, not in aggregate. A physician who has performed 200 PRP injections is not necessarily competent at adipose mini-liposuction. A physician who has performed 100 intra-articular knee injections is not necessarily competent at intrathecal CNS delivery for advanced neurological indications.

The procedure-specific questions to ask:

Adipose mini-liposuction (for autologous adipose-derived stem cell protocols):

How many adipose mini-liposuctions has the physician performing my procedure personally performed in the past 12 months?
How many in their career?
Realistic answer at a serious practice: tens per year, hundreds in career for the senior practitioners.
Red flag: cannot provide a number, deflects to "the team's experience," or numbers in the single digits.

Stromal vascular fraction (SVF) processing or cell isolation:

Who performs the SVF processing — the physician, a dedicated processing technician, or a third-party laboratory?
What is the processing protocol (enzymatic vs mechanical, manual vs closed-system device)?
What is the cell viability percentage at delivery, and how is it documented?
Realistic answer: dedicated processing technician or closed-system device, viability >85%, documented per case.
Red flag: "we don't measure viability" or "the kit handles it."

IV systemic stem cell administration:

How many IV systemic stem cell administrations does this clinic perform per month?
What is the patient screening protocol for systemic administration (cardiac clearance, pulmonary screening, infusion-rate protocol)?
Realistic answer: structured screening, infusion-rate protocol, emergency response training documented.
Red flag: no structured screening or infusion-rate protocol.

Intra-articular injection (knee, hip, shoulder, etc.):

Is the injection ultrasound-guided or fluoroscopy-guided?
How many ultrasound-guided intra-articular injections has the physician performed?
Realistic answer: ultrasound or fluoroscopy guidance, hundreds of cases for the joint in question.
Red flag: blind landmark-based injection in joints where guidance is the standard of care.

Intrathecal or CNS delivery (for advanced neurological indications):

Who performs the intrathecal access — a neurosurgeon, an interventional radiologist, an experienced anesthesiologist?
How many intrathecal cell deliveries has this provider personally performed?
Realistic answer: appropriately specialized provider with documented procedural volume.
Red flag: a general practitioner performing intrathecal delivery, or refusal to specify the providing physician.

Scalp microinjection (for hair restoration):

How many scalp microinjection sessions does the clinic perform per month?
What is the injection density protocol (sites per cm², depth, volume per site)?
Realistic answer: structured protocol, hundreds of sessions per year.
Red flag: vague protocol description.

The pattern across all of these: a serious practice answers the volume question in five seconds with a specific number. A clinic that has not built procedural volume in the specific procedure deflects.

Domain 2: Cell Processing Facility Specifications and Chain of Custody

The cell processing facility is where the difference between "stem cell therapy" and "an injection of an undefined biological preparation" is determined. For autologous protocols, the processing happens in real time at or near the clinic. For allogeneic protocols, the processing happens at a manufacturing facility (see our companion piece "Exosome Therapy in Colombia — What's Actually in That Vial?" for the manufacturing-facility verification framework, which applies analogously to allogeneic stem cell products).

For the autologous case (adipose-derived stem cells from a same-day mini-liposuction, the most common protocol in serious Medellín clinics), the cell processing facility verification questions:

Clean-room classification:

What is the ISO classification of the cell processing area?
Realistic answer at a serious practice: ISO Class 7 (or better) at the critical processing steps, ISO Class 8 at the surrounding area, with documented HEPA filtration and air-change rate.
Red flag: "we use a sterile field" without classified clean-room specification.

Processing system:

Is the cell processing performed in an open manual system or a closed-system automated device?
Closed-system devices (such as the Cytori Celution, Tissue Genesis, InGeneron, or similar regulated devices) reduce contamination risk and improve lot-to-lot consistency. Open manual processing can be performed competently but requires more rigorous technique and validation.
Either is acceptable in the right hands. The question is whether the facility can describe their system and validation specifically.

Cell viability testing:

What is the cell viability percentage measured in the processed product before administration?
What method is used (trypan blue, 7-AAD, fluorescence-based)?
How is viability documented per patient per dose?
Realistic answer: viability >85%, documented per case, with method specified.
Red flag: viability is not measured or "the device handles it" without documentation.

Cell count and dose verification:

What is the total nucleated cell count delivered per dose?
What is the cell concentration in the injection volume?
How are the count and concentration documented for the patient's record?
Realistic answer: specific cell count documented per dose (typically ranging from tens of millions to hundreds of millions for a typical adipose-derived autologous protocol).
Red flag: no cell count documentation.

Sterility validation:

Is sterility testing performed on the processed product (or on a representative sample of the lot for allogeneic products)?
What is the response protocol if a sterility breach is detected?
Realistic answer: sterility testing per appropriate protocol, with documented response procedure.

Chain of custody:

For autologous protocols: who handles the harvested tissue from harvest through processing through administration, and how is the chain documented?
For allogeneic protocols: who is the manufacturer, where is the manufacturing facility, what is the cold-chain documentation from manufacture through administration?
Realistic answer: documented chain of custody at every step.

A serious clinic answers all of the above without hesitation. A clinic that cannot answer them is administering a product they have not characterized.

Domain 3: Adverse Event Tracking and Rate

Every procedural medicine has adverse events. The question is not whether a clinic has had any — every honest clinic has — but whether the clinic has a structured adverse event tracking system that captures, classifies, reports, and learns from them.

The questions to ask:

Tracking system:

Does the clinic have a written adverse event tracking system?
Who is responsible for adverse event capture and review?
Realistic answer: yes, with named medical director responsible, with structured review process.
Red flag: "we have not had any problems" without a tracking system. A clinic without a tracking system has no way of knowing whether it has had problems.

Classification:

How are adverse events classified by severity (mild, moderate, severe, life-threatening)?
Realistic answer: a Common Terminology Criteria for Adverse Events (CTCAE) or similar classification framework.

Reporting:

Are serious adverse events reported to INVIMA through the FOREAM system (Formato de Reporte de Eventos Adversos)?
Realistic answer: yes, with documented reporting protocol.
Red flag: clinic does not know what FOREAM is or claims it does not apply to them.

Disclosure:

Will the clinic disclose its overall adverse event rate to a prospective patient?
The honest answer at a serious practice is a low single-digit percentage for minor events (transient injection-site soreness, transient infusion-related symptoms, etc.) and a vanishingly small fraction of a percent for serious events.
Red flag: refusal to discuss adverse event rate, or claims of zero adverse events ever (statistically implausible at any meaningful procedural volume).

Learning loop:

When an adverse event occurs, what changes in clinic protocol have resulted from past adverse event review?
Realistic answer: the clinic can give specific examples of protocol refinements that came from adverse event review.
Red flag: no examples — meaning no learning loop exists.

For the broader patient-side regulatory framework — how to file an adverse event report through FOREAM yourself if needed, how to access the Tutela mechanism for urgent care concerns — see the "Verifying Your Medellín Peptide Clinic on Day 1" companion piece.

Domain 4: Long-Term Follow-Up Infrastructure

The most consistent structural difference between serious regenerative practices and surface-level operations is what happens to the patient at 6 and 12 months after the procedure. A serious practice has built the infrastructure to retain patients for structured follow-up. A surface-level operation collects payment, performs the procedure, and loses the patient.

Long-term follow-up matters for three reasons:

Outcome data integrity. A clinic that does not collect 6/12-month outcome data does not actually know what its outcomes are. Anecdotal "we get great results" claims that are not backed by structured outcome tracking are uninformative.

Patient care continuity. Stem cell therapy outcomes evolve over months. The patient who is doing well at 4 weeks may need an adjustment at 4 months. The clinic that has lost the patient cannot make the adjustment.

Adverse event detection. Some adverse events emerge weeks or months post-procedure. Without follow-up infrastructure they go undetected and unreported.

The follow-up infrastructure questions:

Follow-up schedule:

What is the structured follow-up schedule post-procedure (e.g., 2-week, 6-week, 3-month, 6-month, 12-month)?
Realistic answer: specific scheduled touchpoints at named intervals.
Red flag: "call us if you have problems" with no structured outreach.

Telemedicine continuity:

For U.S. patients returning home, is there a telemedicine continuity protocol?
Who is the named physician or coordinator responsible for the U.S. patient's post-trip continuity?
See our companion piece "Peptide Therapy: Post-Trip Continuation Care, Telemedicine, and Supply for Americans Returning Home (2026)" for the broader telemedicine continuity framework.

Outcome measurement:

What outcome measures does the clinic track (validated patient-reported outcome measures such as KOOS, WOMAC, VAS pain scale for orthopedic indications; SF-36 or PROMIS for general health; Norwood scale photography for hair; etc.)?
Realistic answer: validated outcome measures appropriate to the indication, captured at structured intervals.
Red flag: no outcome measurement beyond patient self-report at the moment of contact.

Outcome data availability:

Will the clinic share aggregate outcome data for patients with my specific indication?
A serious practice can produce aggregate response-rate data, durability-of-response data, and adverse event data for the indications it treats with meaningful volume.
Red flag: no aggregate data, only testimonials.

Retention rate:

What percentage of patients complete the 6-month and 12-month follow-up touchpoints?
A clinic with strong infrastructure retains 60-80% of patients at 12 months. A clinic with no infrastructure retains under 20%.
Red flag: clinic cannot provide a retention rate.

The "Stem Cell Mill" Problem: When Volume Becomes Its Own Red Flag

The volume-outcome relationship has a sweet spot. Very low volume is a red flag for inexperience. Very high volume — beyond a certain threshold — can be a different kind of red flag.

The "stem cell mill" pattern is a clinic that has industrialized stem cell delivery to the point of losing patient individualization. The signs:

Identical protocol for every patient regardless of indication, severity, or comorbidities.
15-minute consultations followed by same-week procedures with no diagnostic workup.
Cell processing performed in batches with no per-patient documentation.
No structured follow-up infrastructure (the volume model depends on patient throughput, not patient retention).
Marketing emphasis on "thousands of patients treated" without any mention of indication-specific outcome data.
Heavy reliance on commission-paid medical tourism brokers as the primary patient acquisition channel.

The honest framing: a clinic at the right volume — high enough to have built procedural competence and processing infrastructure, low enough to maintain per-patient individualization, diagnostic rigor, and structured follow-up — is the goal. Not the highest possible volume.

A useful heuristic: ask the clinic what their typical first-consultation length is. A serious practice spends 45-90 minutes on the first consultation for a complex regenerative case. A stem cell mill spends 15.

Realistic Answers vs Red-Flag Answers Summary

Domain	Realistic Answer	Red-Flag Answer
Adipose mini-lipo volume	Specific number, tens per year, hundreds in career	"The team has lots of experience"
Cell processing	ISO-classified, viability >85% documented per case	"We use a sterile field," no viability data
Cell count delivered	Specific number per dose, documented	No documentation
Adverse event tracking	Written system, named medical director, FOREAM reporting	"We've never had any problems"
Adverse event disclosure	Honest single-digit % for minor events	"Zero adverse events ever"
Follow-up schedule	Specific intervals (2-week, 6-week, 3-month, 6-month, 12-month)	"Call us if you have problems"
Outcome measurement	Validated PROMs (KOOS, WOMAC, etc.)	Patient self-report only
Retention at 12 months	60-80%	Cannot provide a number
First consultation length	45-90 minutes for complex case	15 minutes

Who Is and Is NOT a Candidate for Stem Cell Therapy in Medellín

This article assumes you have already read our broader candidacy framework in the companion stem cell articles. The summary:

Candidates

Patients with imaging-confirmed orthopedic pathology amenable to regenerative protocol (early to moderate osteoarthritis, partial tendon tears, cartilage defects, degenerative disc changes).
Patients with skin and aesthetic indications appropriate for stem cell adjuncts.
Patients with hair restoration indications on viable miniaturizing follicles.
Patients with selected systemic and longevity indications, with realistic expectation framing.
Patients who have completed appropriate diagnostic workup and conservative management trials.

Not candidates

Active malignancy or recent malignancy (case-by-case clearance).
Active untreated infection.
Pregnancy and breastfeeding.
Severe organ dysfunction precluding the procedure.
Patients on immunosuppressant therapy that cannot be safely coordinated.
Patients seeking guarantees that defy the biology.
Patients seeking single-day intervention for conditions that require structured rehabilitation in addition to the regenerative procedure.

Frequently Asked Questions

1. How do I find out a Colombian physician's procedural volume? Is there a registry?

There is no public registry of physician-specific procedural volume in Colombia (or in most countries). The information comes from asking the physician directly. A serious physician answers in five seconds with a specific number. A physician who deflects has answered the question in a different way.

2. Should I require a cell viability percentage in writing before the procedure?

You should request that cell viability and cell count delivered be documented in your medical record. A serious practice provides this as standard documentation.

3. What is a reasonable cell viability percentage at delivery?

Above 85% is a reasonable threshold for a typical autologous adipose-derived protocol with current processing technology. Above 90% is excellent.

4. How do I know if the clinic's reported outcomes are real or marketing?

Validated patient-reported outcome measures (KOOS, WOMAC, VAS, SF-36, etc.) collected at structured intervals are real. Testimonials and "before/after" photographs without structured outcome measurement are marketing.

5. What is the FOREAM system?

INVIMA's Formato de Reporte de Eventos Adversos — the Colombian regulatory adverse event reporting system. Clinics performing biological product administration are expected to report serious adverse events. A clinic that does not know what FOREAM is has not engaged with the regulatory framework. See the "Verifying Your Medellín Peptide Clinic on Day 1" article for patient-side use.

6. Is high volume always good?

No. High volume with maintained per-patient individualization, structured workup, and structured follow-up is good. High volume in the "stem cell mill" pattern (identical protocol for every patient, 15-minute consultations, no follow-up infrastructure) is a different kind of red flag.

7. How long should my first consultation be?

For a complex regenerative case, 45-90 minutes. For a straightforward indication, 30 minutes minimum. Anything under 20 minutes for a stem cell consultation is a red flag.

8. Can I ask for the names of the providers performing each step of my procedure?

Yes, and you should. The harvest physician, the processing technician, and the administering physician should all be named in your record. A clinic that will not name the providers is operating with reduced accountability.

9. What if a clinic has good credentials but cannot answer the volume questions?

The clinic may still be appropriate for procedures it performs frequently and inappropriate for procedures it does not. Ask about your specific procedure. If the volume answer is low, consider another clinic.

Every plan is personalized. Message us on WhatsApp and we'll send your quote after reviewing your case.

The program is structured around documented physician volume for each procedure type, ISO-classified cell processing with per-case viability and cell count documentation, structured adverse event tracking with FOREAM integration, and 6-month and 12-month follow-up infrastructure with named telemedicine continuity. The verification framework is the operational standard, not a marketing checklist.

Cross-Linked Companion Guides

Verifying Your Medellín Peptide Clinic on Day 1: The On-the-Ground Patient Protection Checklist (2026) — for the binary credential layer (RETHUS, REPS, FOREAM, Tutela) that this article assumes you have already completed.
Exosome Therapy in Colombia — What's Actually in That Vial? (2026) — for the analogous manufacturing-facility verification framework for allogeneic exosome products.
Cost-Per-Result: When PRP Beats Exosomes Beats Stem Cells in Medellín (2026) — for the buyer's economic decision framework.
Combined Peptide + Stem Cell Therapy in Medellín: The Clinical Sequencing Guide (2026) — for the protocol design framework once verification is complete.
Peptide Therapy: Post-Trip Continuation Care, Telemedicine, and Supply for Americans Returning Home (2026) — for the long-term follow-up infrastructure detail.
Peptide Therapy in Colombia: INVIMA Standards, Safety & Regulations (2026) — for the broader regulatory framework background.

Who This Article Is NOT For

Patients seeking the cheapest possible stem cell procedure regardless of practitioner volume or processing infrastructure.
Patients who consider asking the volume questions impolite. (They are not. A serious practitioner welcomes them.)
Patients seeking single-day intervention for conditions that require structured rehabilitation in addition to the procedure.
Patients seeking guaranteed cures.

The Bottom Line

Credentials are necessary. They are not sufficient. After the binary credential checks, the predictive layer is procedural volume by procedure, cell processing facility specifications, structured adverse event tracking, and long-term follow-up infrastructure.

A serious practice answers all four-domain questions in five minutes. A practice that cannot, regardless of how impressive its credentials look on paper, has not built the infrastructure that makes the credentials translate into outcomes.

The patient who asks the four-domain questions before booking is not being difficult. They are being the kind of patient that serious practices want.

Schedule a Consultation

YouMedicine in El Poblado, Medellín operates the four-domain verification framework as standard infrastructure. Documented physician procedural volume, ISO-classified cell processing with per-case viability and cell count documentation, structured adverse event tracking with FOREAM integration, and structured 6-month and 12-month follow-up with named telemedicine continuity for U.S. patients.

Email: wellness@youmedicine.co
WhatsApp: +57 324 576 1913
Location: El Poblado, Medellín, Colombia

In your first message, request:

The procedural volume of the physician who would perform your specific procedure
The cell processing facility specifications and chain-of-custody documentation
The clinic's adverse event tracking and rate disclosure
The follow-up schedule and 12-month patient retention rate